Browse everything: Tickers A–Z · Issuers · Comparisons · Tags
APGE Stock — Apogee Therapeutics, Inc.
No longer trading. This fund has been liquidated; the figures below are frozen at its final trading day.
Apogee Therapeutics, Inc. (APGE)
Updated September 2, 2026.
Apogee Therapeutics develops biologic therapies for immunological and inflammatory diseases, with a pipeline of monoclonal antibodies and combination therapies targeting conditions including atopic dermatitis, asthma, and eosinophilic esophagitis, along with antibody engineering services. The company does not currently distribute to shareholders. This security appeals to those seeking exposure to early-stage biopharmaceutical development rather than income generation.
APGE key facts
- Asset type
- Stock
- Asset class
- Equity
- Inception date
- 07/13/2023
- Distribution frequency
- None
- Last close
- $135.07 (stale; as of 2026-09-02)
- Market cap
- $10,223,142,912
- Average volume
- 2,925,094
- Beta
- 0.327
- Payout ratio
- 0.0%
- Forward P/E
- -26.00
- EPS
- -$4.34
Tickers
Holdings as-of date unavailable.
| Ticker | Name | Weight |
|---|
See how this investment would fit into your portfolio.